Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.
People who have already been sick with Covid-19 should still be vaccinated, experts say, but they may experience intense side effects even after one dose.
To speed inoculations, the U.S. plans to release all available vaccine doses and open access to anyone over 65. Others suggest straying from recommended doses or intentionally delaying boosters. The best way forward remains uncertain.
Once immunity is widespread in adults, the virus rampaging across the world will come to resemble the common cold, scientists predict.